Young People Get Osteoporosis Too 

Butterfly1b1  VIVELLEButterfly1b5


Free E Cards • Email




Please be advised that the inclusion of any medication on this site is not indicative of an endorsement.  I do not have any affiliation with the pharmaceutical corporations that manufacture prescription osteoporosis medications.  I am not a doctor, therefore I am not medically qualified to counsel or advise osteoporosis patients about which medication is best suited for their individual case.

 • actonel • aredia • boniva • didronel • evista • Forteo • fosamax • miacalcin • zometa • vivelle • reclast •

NEW YORK (Reuters) - Noven Pharmaceuticals Inc. said Friday that its treatment for menopausal symptoms, Vivelle, has been additionally approved by U.S. regulators to address postmenopausal osteoporosis.
The company said Vivelle, which has been on the market to address the effects of menopause since March 1996, has received U.S. Food and Drug Administration approval to fight the bone disease.

The product delivers estradiol, the primary estrogen produced by the ovaries, through a patch that is applied twice per week, the Miami, Fla.-based company said. Four dosages of Vivelle are currently available and the company said a fifth, lower dosage was approved by the FDA for the treatment of osteoporosis.

 Doctors now have a new, effective treatment option to help patients reduce their risk of developing postmenopausal osteoporosis. The U.S. Food and Drug Administration (FDA) has approved an existing transdermal estrogen patch, marketed by Novogyne Pharmaceuticals, a joint venture between Noven Pharmaceuticals, Inc. and Novartis Pharmaceuticals Corporation, for the prevention of postmenopausal osteoporosis. The patch, sold under the Vivelle brand name, has been available for the treatment of menopausal symptoms since March 1996.
Vivelle is available by prescription and utilizes Noven's transdermal matrix technology. The product delivers estradiol, the primary estrogen produced by the ovaries, through a patch that is applied twice weekly.

Vivelle is now indicated for the prevention of osteoporosis and currently available in four dosage strengths (0.0375, 0.05, 0.075 and 0.1 mg/day). A new low dose of Vivelle, 0.025 mg/day, is expected to be available in U.S. pharmacies in late 2000. The 0.025 mg/day dosage strength is about the size of a quarter.

After menopause, a woman can lose up to 20% of her bone mass, making her more susceptible to osteoporosis. In the U.S., 80 percent of those suffering from osteoporosis are women. "Use of hormone replacement therapies, such as Vivelle, can help reduce the risk of osteoporosis and, at the same time, help women experiencing menopause ease menopausal symptoms such as hot flashes, night sweats and vaginal dryness," said W. Neil Jones, Executive Director Marketing and    Sales at Noven Pharmaceuticals, Inc.

In clinical trials, systemic adverse events with Vivelle (estradiol transdermal system) and placebo, respectively, include headache (36% vs. 30%), breast tenderness (4.9% vs. 1.1%), fluid retention (3.8% vs. 2.2%) and back pain (13% vs. 4.5%). Local application site reactions with Vivelle were approximately 9% vs. 10% in patients treated with placebo; most cases were considered mild, none were considered severe.

Estrogens should not be used in individuals with known or suspected pregnancy, undiagnosed abnormal genital bleeding, breast cancer, estrogen- dependent neoplasia, active thrombophlebitis or thromboembolic disorders, or a documented history of these conditions. Estrogens have been reported to increase the risk of endometrial carcinoma in postmenopausal women.

Vivelle is marketed by Novogyne Pharmaceuticals, a joint venture between Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, and Noven Pharmaceuticals, Inc. of Miami, Florida.

Vivelle Prescribing Information is available at, or by calling (888) NOW-NOVA.